title: Expression of cyclin D1/2 in the lungs of strain A/J mice fed chemopreventive agents.
abstract: Male strain A mice were fed a diet containing chemopreventive agents. After 1 and 3 weeks on the diets, lung nuclear fractions were examined for expression of cyclin D1/2 with western blot analysis. In animals fed a diet containing a mixture of myoinositol and dexamethasone, a treatment found previously to be effective in preventing the development of tobacco smoke-induced lung tumors in A/J mice, cyclin D1/2 expression was reduced to 30-40% of control levels. A similar decrease in cyclin D1/2 expression was found when animals were fed either myoinositol or dexamethasone alone. Paradoxically, tobacco smoke by itself had a similar effect on cyclin D1/2 expression. On the other hand, several agents that had been previously found not to be effective against tobacco smoke carcinogenesis [phenethyl isothiocyanate, 1,4-phenylenebis(methylene)selenoisocyanate, N-acetylcysteine, acetylsalicylic acid, D-limonene and beta carotene] did not decrease cyclin D1/2 expression after 1 or 3 weeks of feeding. It was concluded that expression of cyclin D1/2 might be a potentially useful marker in the identification of chemopreventive agents for tobacco smoke and could be of some help in the evaluation of their effects.
authors.affiliation: Center for Health and the Environment and Department of Molecular Biosciences, School of Veterinary Medicine, University of California, One Shields Avenue, Davis, CA 95616, USA. hrwitschi@ucdavis.edu
authors.forename: Hanspeter
authors.initials: H
authors.lastname: Witschi
authors.forename: Imelda
authors.initials: I
authors.lastname: Espiritu
authors.forename: Marie
authors.initials: M
authors.lastname: Suffia
authors.forename: Kent E
authors.initials: KE
authors.lastname: Pinkerton
mesh_terms: D000111:Acetylcysteine / Q000494:pharmacology; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D015153:Blotting, Western; D002467:Cell Nucleus / Q000187:drug effects; D019938:Cyclin D1 / Q000096:biosynthesis*; D056742:Cyclin D2; D016213:Cyclins / Q000096:biosynthesis*; D053138:Cyclohexenes; D003907:Dexamethasone / Q000494:pharmacology; D016166:Free Radical Scavengers / Q000494:pharmacology; D007150:Immunohistochemistry; D007294:Inositol / Q000494:pharmacology; D017879:Isothiocyanates / Q000494:pharmacology; D000077222:Limonene; D008168:Lung / Q000187:drug effects; D008175:Lung Neoplasms / Q000139:chemically induced / Q000517:prevention & control; D008297:Male; D051379:Mice; D016566:Organoselenium Compounds / Q000494:pharmacology; D013662:Tea; D013729:Terpenes / Q000494:pharmacology; D013997:Time Factors
chemical_list: D016588:Anticarcinogenic Agents; C486196:Ccnd2 protein, mouse; D056742:Cyclin D2; D016213:Cyclins; D053138:Cyclohexenes; D016166:Free Radical Scavengers; D017879:Isothiocyanates; D016566:Organoselenium Compounds; D013662:Tea; D013729:Terpenes; D019938:Cyclin D1; D007294:Inositol; C058305:phenethyl isothiocyanate; D003907:Dexamethasone; C074153:1,4-phenylenebis(methylene)selenocyanate; D000077222:Limonene; D001241:Aspirin; D000111:Acetylcysteine